Loading…
Poly Medicure (POLYMED)₹1,614+0.99%Medical Equipment & Supplies
In the Jun 2026 quarter (consolidated), Poly Medicure reported sales of ₹526 Cr, up 30.3% from Jun 2025, and net profit of ₹85.29 Cr, down 8.6% year on year. For the year to Mar 2026, sales were ₹1,876 Cr and net profit ₹322 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 337 | 340 | 378 | 385 | 420 | 424 | 441 | 403 | 444 | 494 | 535 | 526 |
| Expenses | 253 | 249 | 282 | 282 | 306 | 310 | 322 | 298 | 330 | 383 | 425 | 400 |
| Operating Profit | 84.15 | 90.26 | 96.21 | 104 | 115 | 114 | 119 | 106 | 115 | 111 | 110 | 125 |
| OPM % | 25.0% | 27.0% | 26.0% | 27.0% | 27.0% | 27.0% | 27.0% | 26.0% | 26.0% | 23.0% | 21.0% | 24.0% |
| Other Income | 14.99 | 17.01 | 15.01 | 17.01 | 26.99 | 24.01 | 27.03 | 43.03 | 35.03 | 21.01 | 19.01 | 34.99 |
| Interest | 2.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 2.01 | 3.01 | 3.01 | 6.01 | 6.01 | 6.01 |
| Depreciation | 16.04 | 16.06 | 16.04 | 20.06 | 21.05 | 21.07 | 21.05 | 23.07 | 25.09 | 29.07 | 38.09 | 36.09 |
| Profit before tax | 81.22 | 88.26 | 92.36 | 98.33 | 118 | 113 | 123 | 123 | 122 | 98.34 | 85.28 | 117 |
| Tax % | 23.0% | 26.0% | 26.0% | 25.0% | 26.0% | 25.0% | 25.0% | 24.0% | 25.0% | 27.0% | 24.0% | 27.0% |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | −4.99 | 0.00 | 0.00 |
| Net Profit | 62.25 | 65.25 | 68.23 | 74.32 | 87.39 | 85.33 | 92.30 | 93.30 | 92.40 | 71.24 | 65.25 | 85.29 |
| EPS (Rs) | 6.46 | 6.76 | 7.10 | 7.69 | 8.61 | 8.39 | 9.04 | 9.16 | 9.03 | 6.98 | 6.53 | 8.47 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 412 | 454 | 519 | 611 | 687 | 785 | 923 | 1,116 | 1,377 | 1,669 | 1,876 | 1,999 |
| Expenses | 323 | 361 | 397 | 480 | 521 | 570 | 708 | 848 | 1,015 | 1,216 | 1,435 | 1,537 |
| Operating Profit | 88.22 | 93.25 | 122 | 131 | 166 | 216 | 216 | 268 | 362 | 456 | 443 | 462 |
| OPM % | 21.0% | 21.0% | 23.0% | 22.0% | 24.0% | 28.0% | 23.0% | 24.0% | 26.0% | 27.0% | 24.0% | 23.1% |
| Other Income | 7.99 | 14.01 | 15.99 | 19.99 | 21.01 | 22.02 | 40.01 | 38.02 | 60.05 | 94.10 | 119 | 110 |
| Interest | 10.02 | 8.01 | 12.01 | 14.02 | 20.02 | 11.01 | 6.01 | 11.02 | 14.02 | 14.03 | 18.01 | 21.04 |
| Depreciation | 21.07 | 24.07 | 29.10 | 37.11 | 41.10 | 48.12 | 54.18 | 57.21 | 63.17 | 83.20 | 116 | 128 |
| Profit before tax | 65.18 | 75.27 | 97.32 | 100 | 126 | 181 | 196 | 238 | 345 | 455 | 428 | 423 |
| Tax % | 27.0% | 27.0% | 27.0% | 35.0% | 24.0% | 25.0% | 25.0% | 25.0% | 25.0% | 25.0% | 25.0% | — |
| Exceptional items | 0.00 | 0.99 | 0.00 | 0.99 | 0.00 | 0.99 | 5.99 | 6.99 | 0.00 | 4.99 | −4.99 | −4.99 |
| Net Profit | 48.17 | 55.22 | 71.28 | 65.29 | 96.36 | 137 | 148 | 180 | 259 | 340 | 322 | 314 |
| EPS (Rs) | 5.45 | 6.23 | 7.98 | 7.40 | 10.83 | 14.14 | 15.24 | 18.65 | 26.84 | 33.34 | 31.72 | 31.01 |
| Dividend payout % | 27.0% | 40.0% | 25.0% | 27.0% | 18.0% | 18.0% | 16.0% | 16.0% | 11.0% | 10.0% | 11.0% | — |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 22.06 | 22.05 | 44.13 | 44.13 | 44.16 | 44.14 | 48.10 | 48.10 | 48.14 | 48.15 | 51.06 | 51.14 |
| Reserves | 174 | 207 | 228 | 295 | 338 | 392 | 919 | 1,042 | 1,197 | 1,426 | 2,717 | 3,060 |
| Borrowings | 79.28 | 82.29 | 101 | 133 | 162 | 208 | 137 | 127 | 150 | 175 | 180 | 355 |
| Other Liabilities | 89.43 | 76.36 | 85.41 | 94.45 | 113 | 127 | 122 | 164 | 188 | 216 | 247 | 461 |
| Total Liabilities | 365 | 388 | 459 | 567 | 656 | 770 | 1,226 | 1,380 | 1,582 | 1,864 | 3,195 | 3,928 |
| Fixed Assets | 166 | 183 | 208 | 266 | 307 | 365 | 428 | 490 | 638 | 870 | 1,088 | 1,709 |
| CWIP | 9.99 | 13.99 | 20.02 | 18.01 | 19.01 | 25.01 | 20.99 | 43.01 | 77.99 | 76.06 | 101 | 91.06 |
| Investments | 3.99 | 3.99 | 2.99 | 16.96 | 7.97 | 24.93 | 353 | 345 | 126 | 167 | 1,074 | 753 |
| Other Assets | 186 | 188 | 228 | 265 | 322 | 355 | 423 | 501 | 740 | 751 | 933 | 1,375 |
| Inventories | 58.06 | 46.04 | 62.03 | 73.07 | 84.02 | 112 | 126 | 168 | 209 | 221 | 286 | 434 |
| Trade receivables | 63.01 | 83.01 | 96.04 | 113 | 128 | 127 | 156 | 207 | 235 | 270 | 350 | 531 |
| Cash & equivalents | 19.95 | 21.96 | 22.95 | 19.95 | 54.92 | 24.97 | 29.95 | 14.98 | 183 | 147 | 151 | 87.79 |
| Total Assets | 365 | 388 | 459 | 567 | 656 | 770 | 1,226 | 1,380 | 1,582 | 1,864 | 3,195 | 3,928 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | 63.05 | 63.01 | 56.09 | 75.11 | 106 | 131 | 119 | 123 | 191 | 266 | 240 | 246 |
| Cash from investing activity | −59.21 | −31.10 | −56.19 | −88.23 | −101 | −109 | −437 | −85.26 | −180 | −242 | −1,198 | −226 |
| Cash from financing activity | −5.98 | −30.89 | 0.00 | 15.95 | −4.98 | −20.96 | 316 | −34.90 | −12.97 | −19.96 | 948 | 19.96 |
| Net cash flow | −1.99 | 0.99 | 0.00 | 2.99 | 0.99 | 0.99 | 0.00 | 2.99 | −0.99 | 4.99 | −2.99 | 40.89 |
| Capex | 54.07 | 33.03 | 59.12 | 82.11 | 78.08 | 106 | 95.20 | 156 | 239 | 277 | 332 | 309 |
| Free cash flow | 12.94 | 30.87 | 0.00 | −6.97 | 30.87 | 24.91 | 23.90 | −30.87 | −47.82 | −8.97 | −88.67 | −58.78 |
| CFO / OP % | 101.0% | 87.9% | 79.0% | 80.0% | 102.0% | 100.0% | 75.0% | 79.9% | 93.0% | 94.0% | 73.0% | 79.0% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 60 | 75 | 78 | 80 | 78 | 69 | 73 | 83 | 78 | 73 | 77 | 104 |
| Inventory days | 147 | 113 | 193 | 160 | 185 | 240 | 216 | 217 | 236 | 204 | 232 | 264 |
| Days payable | 100 | 75 | 130 | 95 | 122 | 141 | 110 | 114 | 104 | 88 | 70 | 74 |
| Cash conversion cycle | 107 | 112 | 141 | 145 | 140 | 167 | 180 | 186 | 210 | 189 | 240 | 295 |
| Working capital days | 24 | 34 | 54 | 70 | 55 | 41 | 73 | 80 | 68 | 53 | 73 | 248 |
| ROCE % | 30.0% | 26.0% | 24.0% | 26.0% | 22.0% | 25.0% | 22.0% | 17.0% | 18.0% | 24.0% | 20.0% | 14.0% |
For the Jun 2026 quarter, Poly Medicure reported sales of ₹526 Cr, up 30.3% year on year and net profit of ₹85.29 Cr, down 8.6% year on year. The operating margin was 24.0%.
Poly Medicure's sales for the year to Mar 2026 were ₹1,876 Cr; over the last twelve months they were ₹1,999 Cr.
Net profit for the year to Mar 2026 was ₹322 Cr, and ₹314 Cr over the last twelve months. Earnings per share over the same trailing period were ₹31.01.
Poly Medicure reported borrowings of ₹355 Cr at Mar 2026, against cash and equivalents of ₹87.79 Cr.
Cash from operations was ₹246 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹58.78 Cr.